.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 6,071,948

« Back to Dashboard

Details for Patent: 6,071,948

Title: Methods and compositions for inhibition of angiogenesis
Abstract:The present invention comprises a group of compounds that effectively inhibit angiogenesis. More specifically, thalidomide and various related compounds such as thalidomide precursors, analogs, metabolites and hydrolysis products have been shown to inhibit angiogenesis. Importantly, these compounds can be administered orally.
Inventor(s): D'Amato; Robert (Lancaster, PA)
Assignee: The Children's Medical Center Corporation (Cambridge, MA)
Filing Date:Oct 16, 1997
Application Number:08/950,673
Claims:1. A method of treating undesired angiogenesis sensitive to EM-138 comprising administering to a human or animal with undesired angiogenesis a composition comprising an effective amount of EM-138 ##STR19##

2. The method of claim 1 wherein the undesired angiogenesis occurs in Kaposi's sarcoma.

3. The method of claim 1 wherein the undesired angiogenesis occurs in hemangiomas.

4. The method of claim 1 wherein the undesired angiogenesis occurs in Osler-Weber-Rendu disease.

5. The method of claim 1 wherein the undesired angiogenesis occurs in solid tumors sensitive to EM-138.

6. The method of claim 1 wherein the undesired angiogenesis occurs in blood borne tumors.

7. The method of claim 1 wherein the undesired angiogenesis occurs in the tumors of rhabdomyosarcoma.

8. The method of claim 1 wherein the undesired angiogenesis occurs in the tumors of retinoblastoma.

9. The method of claim 1 wherein the undesired angiogenesis occurs in the tumors of Ewing's sarcoma.

10. The method of claim 1 wherein the undesired angiogenesis occurs in the tumors of neuroblastoma.

11. The method of claim 1 wherein the undesired angiogenesis occurs in the tumors of osteosarcoma.

12. The method of claim 1 wherein the undesired angiogenesis occurs in leukemia.

13. The method of claim 1 wherein the undesired angiogenesis occurs in neurofibroma.

14. The method of claim 1 wherein the amount administered is between approximately 0.1 and approximately 300 mg/kg/day.

15. The method of claim 1 wherein the amount administered is between approximately 0.5 and approximately 50 mg/kg/day.

16. The method of claim 1 wherein the amount administered is between approximately 1 and approximately 10 mg/kg/day.

17. The method of claim 1 wherein the compound is administered in the form of a tablet.

18. The method of claim 1 wherein the compound is administered in the form of a capsule.

19. The method of claim 1 wherein the compound is administered in the form of a lozenge, a cachet, a solution, a suspension, an emulsion, a powder, an aerosol, a suppository, a spray, a pastille, an ointment, a cream, a paste, a foam, a gel, a tamport, or a pessary.

20. The method of claim 1 wherein the administration is oral.

21. The method of claim 1, wherein the administration is sublingual, buccal, rectal, vaginal, or nasal.

22. The method of claim 1, wherein the administration is parenteral.

23. The method of claim 1, wherein the administration is transdermal or topical.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc